Matchar, D
10.1080/14017430601049449 [DOI] [PubMed] 56.Berlin R, Berlin H, Brante G, Pilbrant
W., Ouyang, K., Anzala, O., Ogengo, J
Keywords: Obesity, Type 2 diabetes, GLP-1RA, Incretin therapy, Pharmacotherapy for obesity, Weight management, GLP1/GIP dual agonists, GLP-1/Glucagon dual agonists, GLP1/GIP/Glucagon triple agonists, Metabolism, Energy expenditure, Insulin secretion Introduction Obesity and type 2 diabetes (T2DM) are two of the most common noncommunicable diseases (NCDs) in the world
Changes were observed under a light microscope
Luddi A, Pavone V, Semplici B, Governini L, Criscuoli M, Paccagnini E, Gentile M, Morgante G, Leo V, Belmonte G, Zarovni N, Piomboni P (2020) Organoids of human endometrium: A powerful in vitro model for the Endometrium-Embryo Cross-Talk at the implantation site